Compare AbCellera Biologics Inc (ABCL) vs Impinj Inc (PI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Impinj Inc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Impinj Inc trades at $142.9 (market cap $4.20B). The key difference: Impinj Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | PI | |
|---|---|---|
Market Cap | $2.35B | $4.20B |
Sector | Health | Technology |
52-Week High | $8.12 | $241.91 |
52-Week Low | $2.78 | $91.34 |
Enterprise Value | $1.99B | $4.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Impinj (PI) trades at $148.00, up 4.53% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $167.50. Recent Q1 2026 earnings beat expectations, but the company shows negative net income margins and elevated valuation multiples. Key news includes upcoming Q2 2026 results and insider selling activity.
The stock offers upside potential from strong analyst buy ratings and RFID technology leadership, but risks include persistent profitability challenges, high debt-to-asset ratio (51.52% in 2025), and sensitivity to earnings misses. Investor sentiment is mixed amid growth execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
